Skip to content

Tag Archives: Fuad El-Hibri

Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

Friday, June 10, 2011

ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]

Filed in Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, U.S. Food and Drug Administration | Also tagged , , , | Comments (0)

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

Tuesday, June 7, 2011

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]

Filed in Biothrax, Chief Executive Officer, Food and Drug Administration, Fuad El-Hibri, U.S. Food and Drug Administration | Also tagged , , , , | Comments (0)

Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference

Wednesday, June 1, 2011

ROCKVILLE, Md., May 25, 2011 — Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in New York on Tuesday, June 7, 2011 at 1:15 PM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]

Filed in Business, El-Hibri, Financial Performance, Fuad El-Hibri, Healthcare Conference, Investors | Also tagged , , , , | Comments (0)

Emergent BioSolutions Reports Financial Results for First Quarter 2011

Thursday, May 12, 2011

ROCKVILLE, Md., May 05, 2011 (BUSINESS WIRE) — Emergent BioSolutionsInc. (NYSE: EBS) announced  its financial results for the first quarter ended March 31, 2011.
For 1Q 2011, total revenues were $18.5 million as compared to $46.8 million in 2010. In addition, for 1Q 2011 the company recorded a net loss of $21.4 million, or $0.61 per [...]

Filed in BioDefense, Biothrax, Business, Chief Executive Officer, Chief financial officer, Revenue | Also tagged , , , , | Comments (0)

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress

Friday, April 15, 2011

ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals [...]

Filed in Chief Executive Officer, El-Hibri, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri | Also tagged , , , | Comments (0)

Emergent BioSolutions to Present Today at Needham & Company Healthcare Conference

Tuesday, April 5, 2011

Emergent BioSolutions Inc. (NYSE: EBS) will be webcasting its presentation at the 10th Annual Needham & Company Healthcare Conference in New York on Tuesday, April 5, 2011 at 8:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate overview, which may include a discussion of [...]

Filed in Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Healthcare Conference | Also tagged , , , | Comments (0)

Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting

Wednesday, December 15, 2010

ROCKVILLE, Md., Dec 06, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) today announced the presentation of positive data from a Phase I dose escalation study of TRU-016 (Protocol 16007) at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In an oral presentation given yesterday, [...]

Filed in Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Hematology, Leukemia & Lymphoma Society, United States | Also tagged , , , , , , | Comments (0)

Fuad El-Hibri Recognized by Vilcek Foundation

Friday, December 10, 2010

The Vilcek Foundation was established in 2000 by Jan and Marica Vilcek, immigrants from the former Czechoslovakia.  The Foundation was established with the aim of raising public awareness around immigrants’ contributions to the sciences, arts, and culture in the United States.  The Foundation’s mission was inspired [...]

Filed in Business, Chief Executive Officer, El-Hibri Peace Education Prize, Emergent Bioslutions, Food and Drug Administration, Fuad, Fuad El-Hibri, Peace Education, Research and development, Yale university | Also tagged , , , , , , | Comments (0)

Fuad El-Hibri and the International Biomedical Research Alliance

Saturday, November 13, 2010

The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate [...]

Filed in Anthrax vaccines, Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States, Washington D.C | Also tagged , , , , , | Comments (0)

Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals

Wednesday, November 3, 2010

ROCKVILLE, Md., Oct 28, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders at a special meeting conducted at Trubion’s Seattle headquarters on October 28, 2010. The acquisition [...]

Filed in Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Seattle, Trubion Pharmaceuticals, United States | Also tagged , , , | Comments (0)